Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vilin Bio MedNSE:VILINBIO +4.93%69 Return-on-Tangible-Equity is 13.82% as of Mar. 2026, which is 733% above its 10-year median of 1.66. GuruFocus rates NSE:VILINBIO with a GF Score™ of 69/100 and a GF Value™ of ₹75.10 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 896 Drug Manufacturers companies, Vilin Bio Med ranks worse than 52.23% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vilin Bio Med's annualized net income for the quarter that ended in Mar. 2026 was ₹35.5 Mil. Vilin Bio Med's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹257.2 Mil. Therefore, Vilin Bio Med's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 13.82%.
The historical rank and industry rank for Vilin Bio Med's Return-on-Tangible-Equity or its related term are showing as below:
NSE:VILINBIO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.45 Med: 1.66 Max: 13.78
Current: 6.91
During the past 7 years, Vilin Bio Med's highest Return-on-Tangible-Equity was 13.78%. The lowest was 0.45%. And the median was 1.66%.
NSE:VILINBIO's Return-on-Tangible-Equity is ranked worse than 52.23% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.59
vs NSE:VILINBIO: 6.91
Vilin Bio Med (NSE:VILINBIO) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Vilin Bio Med Return-on-Tangible-Equity Related Terms
Vilin Bio Med Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Vilin Bio Med's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VILINBIO vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vilin Bio Med's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vilin Bio Med Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vilin Bio Med's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Vilin Bio Med's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 13.82% mean?
Vilin Bio Med (NSE:VILINBIO) has a Return-on-Tangible-Equity of 13.82% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vilin Bio Med and its competitors. This is 733% above median its historical median of 1.66. Over the past decade, Vilin Bio Med's Return-on-Tangible-Equity has ranged from 0.45 to 13.78. According to the industry distribution chart, Vilin Bio Med ranks #468 out of 896 companies in the Drug Manufacturers industry, placing it in the top 52.2%.
Is Vilin Bio Med's Return-on-Tangible-Equity too high?
Vilin Bio Med's current Return-on-Tangible-Equity of 13.82% is 733% above median its 10-year median of 1.66. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 13.78. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.59. Vilin Bio Med's value of 13.82% is 82.1% above this industry median. Based on the distribution chart, Vilin Bio Med ranks #468 out of 896 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vilin Bio Med has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vilin Bio Med's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vilin Bio Med ranks #468 out of 896 companies for Return-on-Tangible-Equity. This places Vilin Bio Med in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.59. Vilin Bio Med's value of 13.82% is 82.1% above this benchmark. Historically, Vilin Bio Med's own Return-on-Tangible-Equity has ranged from 0.45 to 13.78 over the past decade. While the company's 10-year median is 1.66 vs. the industry median of 7.59, Vilin Bio Med has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.59, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vilin Bio Med's current Return-on-Tangible-Equity of 13.82% is 82.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vilin Bio Med and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vilin Bio Med's current Return-on-Tangible-Equity is 13.82%, which is 733% above median its own 10-year median of 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vilin Bio Med stock overvalued right now?
Based on GuruFocus' analysis, Vilin Bio Med (NSE:VILINBIO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹75.10, compared to a current price of ₹44.70 — trading 40.5% below its estimated fair value. The current Return-on-Tangible-Equity is 13.82%, which is 733% above median its 10-year median of 1.66 and 82.1% above the Drug Manufacturers industry median of 7.59. Vilin Bio Med's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Vilin Bio Med (NSE:VILINBIO), the current Return-on-Tangible-Equity is 13.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vilin Bio Med (NSE:VILINBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Vilin Bio Med stock appears to be undervalued.
The current stock price of ₹44.70 is trading 40.5% below its estimated GF Value™ of ₹75.10.
GuruFocus considers Vilin Bio Med to be Possible Value Trap.
Key valuation signals for NSE:VILINBIO:
Return-on-Tangible-Equity: 13.82% (733% above median its 10-year median of 1.66)
GF Value™: ₹75.10 vs. price of ₹44.70 (40.5% below fair value)
Industry Position: 82.1% above the Drug Manufacturers median (#468 of 896)
No single metric tells the full story. See the NSE:VILINBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules and Nutritional Food supplements.
69GF Score
Get the complete analysis for NSE:VILINBIO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VILINBIO has been successfully added to your 
